Abbott reports 30‑percentage‑point sensitivity gain for Oncodetect colorectal cancer MRD test

Abbott presented Beta‑CORRECT data at ESMO 2026 showing its whole‑genome sequencing Oncodetect MRD test achieved 72.2% sensitivity for detecting colorectal cancer recurrence within two years, a 30‑percentage‑point absolute improvement over the previous whole‑exome version (42.2%). The study of 279 post‑surgical patients found a 10.6‑fold higher recurrence risk for those with detectable ctDNA and identified 15 additional ctDNA‑positive cases among 157 patients tested with both assays. Abbott said the results reinforce the prognostic value of highly sensitive MRD testing.

The company says the data support broader clinical adoption of the WGS‑based test, which could expand its diagnostic portfolio and drive future revenue. Analysts note that improved sensitivity may increase test ordering by oncologists, potentially boosting Abbott’s diagnostics sales.

  • 1The WGS‑based Oncodetect test achieved 72.2% sensitivity for recurrence within two years, versus 42.2% for the WES test, a 30‑percentage‑point absolute improvement.
  • 2Patients with detectable ctDNA after surgery had a 10.6‑fold higher risk of recurrence than ctDNA‑negative patients.
  • 3The Beta‑CORRECT study analyzed post‑surgical samples from 279 patients, predominantly stage II and III.
  • 4Among 157 patients tested with both assays, the WGS test detected ctDNA in all 29 patients identified by the WES test plus 15 additional patients.
  • 5Two‑year disease‑free survival rates were 36.2% for ctDNA‑positive patients versus 92.3% for ctDNA‑negative patients.

Sources